[go: up one dir, main page]

CL2017003020A1 - Antibodies against member 4 of the tumor necrosis factor receptor (ox40) superfamily and their uses - Google Patents

Antibodies against member 4 of the tumor necrosis factor receptor (ox40) superfamily and their uses

Info

Publication number
CL2017003020A1
CL2017003020A1 CL2017003020A CL2017003020A CL2017003020A1 CL 2017003020 A1 CL2017003020 A1 CL 2017003020A1 CL 2017003020 A CL2017003020 A CL 2017003020A CL 2017003020 A CL2017003020 A CL 2017003020A CL 2017003020 A1 CL2017003020 A1 CL 2017003020A1
Authority
CL
Chile
Prior art keywords
superfamily
antibodies against
necrosis factor
tumor necrosis
factor receptor
Prior art date
Application number
CL2017003020A
Other languages
Spanish (es)
Inventor
Nils Lonberg
Mohan Srinivasan
Alexander T Kozhich
Alan J Korman
Mark J Selby
Michelle Minhua Han
Indrani Chakraborty
Bryan C Barnhart
Karla A Henning
Ming Lei
Liang Schweizer
Sandra V Hatcher
Zhehong Cai
Marie-Michelle Navarro GARCIA
Thomas D Kempe
Hadia LEMAR
Mark Maurer
Christina Maria Milburn
Michael Quigley
Maria Rodriguez
Xiang Shao
Brenda L Stevens
Kent Thudium
Susan Chien-Szu Wong
Jochem Gokemeijer
xi-tao Wang
Han Chang
Christine Huang
Maria Jure-Kunkel
Zheng Yang
Yan Feng
Patrick Guirnalda
Aaron P Yaminiuk
Arvind Rajpal
Praveen Aanur
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63046422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2017003020A1 publication Critical patent/CL2017003020A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>SE PROPORCIONAN EN LA PRESENTE LOS ANTICUERPOS, O PORCIONES DE FIJACIÓN AL ANTÍGENO DE ÉSTOS, QUE SE FIJAN A OX40. TAMBIÉN SE PROPORCIONAN USOS DE ESTAS PROTEÍNAS EN APLICACIONES TERAPÉUTICAS, POR EJEMPLO, EN EL TRATAMIENTO CONTRA EL CÁNCER. TAMBIÉN SE PROPORCIONAN LAS CÉLULAS QUE PRODUCEN LOS ANTICUERPOS, POLINUCLEÓTIDOS QUE CODIFICAN LA REGIÓN VARIABLE DE LAS CADENAS PESADA Y/O LIGERA DE LOS ANTICUERPOS, Y VECTORES QUE COMPRENDEN LOS POLINUCLEÓTIDOS QUE CODIFICAN LA REGIÓN VARIABLE DE LAS CADENAS PESADA Y/O LIGERA DE LOS ANTICUERPOS.</p><p> ANTIBODIES, OR FIXING PORTIONS ARE PROVIDED TO THE ANTIGEN OF THESE, WHICH ARE FIXED AT OX40. USES OF THESE PROTEINS ARE ALSO PROVIDED IN THERAPEUTIC APPLICATIONS, FOR EXAMPLE, IN THE TREATMENT AGAINST CANCER. ALSO THEY ARE PROVIDED THE CELLS THAT PRODUCE THE ANTIBODIES, POLINUCLEOTIDES THAT CODIFY THE VARIABLE REGION OF THE HEAVY AND / OR LIGHT CHAINS OF THE ANTIBODIES, AND VECTORS THAT UNDERSTAND THE POLINUCLEOTIDES THAT CODIFY THE VARIABLE REGION OF THE VARIABLE BODY . </p>

CL2017003020A 2015-05-29 2017-11-28 Antibodies against member 4 of the tumor necrosis factor receptor (ox40) superfamily and their uses CL2017003020A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168377P 2015-05-29 2015-05-29
US201562239574P 2015-10-09 2015-10-09
US201562264691P 2015-12-08 2015-12-08

Publications (1)

Publication Number Publication Date
CL2017003020A1 true CL2017003020A1 (en) 2018-05-25

Family

ID=63046422

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003020A CL2017003020A1 (en) 2015-05-29 2017-11-28 Antibodies against member 4 of the tumor necrosis factor receptor (ox40) superfamily and their uses

Country Status (1)

Country Link
CL (1) CL2017003020A1 (en)

Similar Documents

Publication Publication Date Title
CO2017013235A2 (en) Antibodies Against Tumor Necrosis Factor Receptor Ox40 Superfamily Member 4
MX374171B (en) Antibodies against the glucocorticoid-induced tumor necrosis factor receptor (GITR) and their uses.
CL2018003153A1 (en) Antibody molecules for the treatment of cancer.
CL2018001369A1 (en) Compositions and methods used to increase the immune response and in cancer therapy (divisional application 201700836)
CO2020014345A2 (en) Gucy2c-specific antibodies and their uses
SV2018005634A (en) ANTI-BCMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN BCMA AND CD3, AND USES OF THESE
EA201891121A1 (en) ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
CO2019000372A2 (en) Antibodies against protein 3 containing the mucin and immunoglobulin domain of T lymphocytes (tim3) and their uses
CL2017000885A1 (en) Humanized anti-ox40 antibodies and their uses
CY1124153T1 (en) ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127
CL2018001512A1 (en) Humanized anti-CD73 antibodies.
CO2018013298A2 (en) Anti-gitr antibodies and their uses.
MX2019004692A (en) Anti-human 4-1 bb antibodies and use thereof.
AR104664A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES AGAINST CADHERINE 6 (ANTI-CDH6)
CL2017000278A1 (en) Bispecific t-cell activating antigen binding molecules
CU20180062A7 (en) HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES
UY35399A (en) CONJUGATES OF DRUGS WITH ANTIBODIES
CU20150128A7 (en) DRUG-ANTIBODY CONJUGATES
MX2020004801A (en) Bispecific fusion polypeptides and methods of use thereof.
GT201500267A (en) ANTI-CD52 ANTIBODIES
CL2017003020A1 (en) Antibodies against member 4 of the tumor necrosis factor receptor (ox40) superfamily and their uses
AR119973A1 (en) COMPOSITIONS AND METHODS OF ANTI-CD39 ANTIBODIES
AR108690A1 (en) ANTIBODIES AGAINST MEMBER 21 OF THE RECEPTOR SUPERFAMILY OF THE TUMOR NECROSIS FACTOR (ANTI-TNFRSF21) AND METHODS OF USE OF THE SAME
EA202090533A2 (en) ANTIBODIES TO OX40 AND THEIR APPLICATION
UY36344A (en) COMPOSITIONS AND METHODS USED TO INCREASE THE IMMUNE RESPONSE AND IN CANCER THERAPY